Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $34 from $30 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note. Truist is positive on Guardian’s leading positioning in the fragmented long-term care pharmacy industry which carries “brisk overarching secular demand drivers”.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN: